AustralianSuper Pty Ltd Sells 90,572 Shares of Boston Scientific Co. (NYSE:BSX)

AustralianSuper Pty Ltd lessened its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 3.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,586,275 shares of the medical equipment provider's stock after selling 90,572 shares during the quarter. Boston Scientific makes up 1.1% of AustralianSuper Pty Ltd's holdings, making the stock its 16th biggest position. AustralianSuper Pty Ltd owned about 0.18% of Boston Scientific worth $231,006,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in BSX. TFC Financial Management Inc. lifted its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 210 shares during the last quarter. Global Wealth Strategies & Associates lifted its holdings in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 250 shares during the last quarter. West Oak Capital LLC acquired a new stake in Boston Scientific during the 4th quarter valued at $29,000. Dunhill Financial LLC lifted its holdings in Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 152 shares during the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Boston Scientific during the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the sale, the executive vice president now owns 5,502 shares in the company, valued at $560,103.60. The trade was a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the sale, the director now owns 39,398 shares of the company's stock, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 88,527 shares of company stock worth $8,801,626 over the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on BSX shares. StockNews.com raised Boston Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, January 29th. Royal Bank of Canada raised their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Piper Sandler lifted their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. JPMorgan Chase & Co. lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. Finally, Mizuho boosted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a report on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Boston Scientific currently has a consensus rating of "Buy" and a consensus price target of $107.39.

Boston Scientific Trading Down 0.7 %

BSX traded down $0.79 during trading on Tuesday, hitting $105.32. The company's stock had a trading volume of 6,505,334 shares, compared to its average volume of 6,108,297. Boston Scientific Co. has a twelve month low of $65.33 and a twelve month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock's fifty day moving average price is $96.79 and its 200-day moving average price is $88.61. The firm has a market capitalization of $155.22 billion, a P/E ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Analysts anticipate that Boston Scientific Co. will post 2.83 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.